Monitoring medicines use: the role of the clinical pharmacologist.

Hdl Handle:
http://hdl.handle.net/10147/270572
Title:
Monitoring medicines use: the role of the clinical pharmacologist.
Authors:
Williams, David
Affiliation:
Department of Geriatric and Stroke Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. davidwilliams@rcsi.ie
Citation:
Monitoring medicines use: the role of the clinical pharmacologist. 2012, 74 (4):685-90 Br J Clin Pharmacol
Journal:
British journal of clinical pharmacology
Issue Date:
Oct-2012
URI:
http://hdl.handle.net/10147/270572
DOI:
10.1111/j.1365-2125.2012.04316.x
PubMed ID:
22554404
Abstract:
Appreciation of the potential of newly marketed medicines to produce both benefit and harm has increased the role of the clinical pharmacologist. Pharmacoepidemiology applies epidemiological reasoning, methods and knowledge to the study of the uses and effects of drugs in human populations. Pharmacovigilence identifies and then responds to safety issues about marketed drugs. Whilst adverse drug reaction (ADR) reporting systems can identify potential problems with drugs, determination of causation requires population-based studies of adverse events (including information from large clinical trials), which attempt to link unequivocally the adverse outcome to the drug in question. Pharmacovigilance is closely linked to postmarketing surveillance and is important for determining issues such as the long-term effects of drugs, identification of low-frequency ADRs, the effectiveness of drugs for their licensed indications or in new indications and other factors which may modify the efficacy and effectiveness of the drug in question. The related field of drug utilization developed in parallel with the study of adverse drug reactions, in recognition of the dramatic increase in the marketing of new drugs, the wide variations in the patterns and extent of drug prescribing, the growing concern about ADRs and the increasing costs of drugs. With the ever increasing number of recognized adverse effects of drugs, prescribing errors, patients' expectations concerning drug safety and the need for appropriate new drug appraisal, the clinical pharmacologist will play an important role both in the introduction of new drugs and in improving the safe and effective use of established drugs.
Item Type:
Article
Language:
en
MeSH:
Adverse Drug Reaction Reporting Systems; Drug Monitoring; Drug Toxicity; Humans; Medication Errors; Pharmacoepidemiology; Pharmacology, Clinical; Pharmacovigilance; Product Surveillance, Postmarketing; Professional Role
ISSN:
1365-2125

Full metadata record

DC FieldValue Language
dc.contributor.authorWilliams, Daviden_GB
dc.date.accessioned2013-02-27T12:28:02Z-
dc.date.available2013-02-27T12:28:02Z-
dc.date.issued2012-10-
dc.identifier.citationMonitoring medicines use: the role of the clinical pharmacologist. 2012, 74 (4):685-90 Br J Clin Pharmacolen_GB
dc.identifier.issn1365-2125-
dc.identifier.pmid22554404-
dc.identifier.doi10.1111/j.1365-2125.2012.04316.x-
dc.identifier.urihttp://hdl.handle.net/10147/270572-
dc.description.abstractAppreciation of the potential of newly marketed medicines to produce both benefit and harm has increased the role of the clinical pharmacologist. Pharmacoepidemiology applies epidemiological reasoning, methods and knowledge to the study of the uses and effects of drugs in human populations. Pharmacovigilence identifies and then responds to safety issues about marketed drugs. Whilst adverse drug reaction (ADR) reporting systems can identify potential problems with drugs, determination of causation requires population-based studies of adverse events (including information from large clinical trials), which attempt to link unequivocally the adverse outcome to the drug in question. Pharmacovigilance is closely linked to postmarketing surveillance and is important for determining issues such as the long-term effects of drugs, identification of low-frequency ADRs, the effectiveness of drugs for their licensed indications or in new indications and other factors which may modify the efficacy and effectiveness of the drug in question. The related field of drug utilization developed in parallel with the study of adverse drug reactions, in recognition of the dramatic increase in the marketing of new drugs, the wide variations in the patterns and extent of drug prescribing, the growing concern about ADRs and the increasing costs of drugs. With the ever increasing number of recognized adverse effects of drugs, prescribing errors, patients' expectations concerning drug safety and the need for appropriate new drug appraisal, the clinical pharmacologist will play an important role both in the introduction of new drugs and in improving the safe and effective use of established drugs.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to British journal of clinical pharmacologyen_GB
dc.subject.meshAdverse Drug Reaction Reporting Systems-
dc.subject.meshDrug Monitoring-
dc.subject.meshDrug Toxicity-
dc.subject.meshHumans-
dc.subject.meshMedication Errors-
dc.subject.meshPharmacoepidemiology-
dc.subject.meshPharmacology, Clinical-
dc.subject.meshPharmacovigilance-
dc.subject.meshProduct Surveillance, Postmarketing-
dc.subject.meshProfessional Role-
dc.titleMonitoring medicines use: the role of the clinical pharmacologist.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Geriatric and Stroke Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. davidwilliams@rcsi.ieen_GB
dc.identifier.journalBritish journal of clinical pharmacologyen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.